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INTRODUCTION
In some oriental populations, the activity of aldehyde
dehydrogenase (ALDH),which is regulatedgenetically,
is reduced hence high concentrations of acetaldehyde
(AcH) are accumulated in blood following ethanol
(EtOH) ingestion (1). AcH, which has a simple chemical
structure and is the firstmetabolite of ethanol, hasmany
pharmacological and physiological actions (2), which
when present at high concentrations in the blood leads
to adverse effects including flushing, headache and
discomfort.
EtOH absorption from the intestine is performed
by simple diffusion (3-5) and this is regulated bymany
factors, including the concentration gradient during
absorption, blood flow at the absorption site, stomach
emptying time, speed of EtOH ingestion and drug
interactions with the gastrointestinal tract (5,6). We
have previously found that accumulation of AcH in
blood inhibits EtOH absorption in canines and rats
with induction of intestinal secretion and reduction
of intestinal blood flow (7-10). In addition, we have also
clarified that such inhibition ismediated by cholinergic
nerves via peripheralmuscarinic receptorsusingatropine,
bethanechol and pilocarpine (11). However, the involve-
ment of other receptors, such as nicotinic or adrenergic
receptor, has not been studied yet.
Hence the main aim of this studywas to investigate
the mechanism of action by examining the effects of
hexamethonium (C6), a ganglionic nicotinic receptor
blocking agents and yohimbine (YO), anα2-adrenergic
antagonist, on the inhibition of intestinal EtOH absorption
through theaccumulationofAcH in theblood.Additionally,
we wished to investigatewhetherother aliphatic aldehyde
compounds can inhibit the absorption of their parent
alcohol, using 1-propanol (PrOH)with cyanamide (CY),
a potent inhibitor of ALDH.
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MATERIALS AND METHODS
MaleWistar rats (273±30g) were used in this study.
The rats were housed in a temperature-controlled en-
vironment (22-24℃), with controlled humidity (50 -
70%) and a standard light/darkness cycle (12/12hrs).
Rats were fasted for 18h prior to experiment, but had
free access to water. Experimental procedures were
performed following pentobarbital anesthesia (50mg/
kg), as previously described (9 -11). Inbrief, catheters
(Intramedic PE-50, Becton Dickinson, Sparks, U.S.A.)
were placed in the femoral artery and vein for sample
collection and drug administration. A 20 cm-length of
jejunum segment was prepared for perfusion of EtOH
or PrOH, after a midline laparotomy. Following the
surgical procedure, the jejunum segment was returned
to the abdominal cavity and abdomen was closed to
maintain the local temperature and humidity. Body
temperature was maintained at 37±0.5℃ throughout
the experiment.
Experiment 1.Ratsweredivided intosixexperimental
groups (5-7 rats/experimental group), as follows :
pretreatment saline (control),CY,YO,CY＋YO,C6 and
CY＋C6. The dose of CY, YO andC6 used in pretreatment
were 50mg/kg, 0.5mg/kg and 10mg/kg, and eachwere
performed 60min, 30min and 10min before EtOHper-
fusion, respectively. Each of these agents was disolved
in saline(0.1 ml/100g body weight). EtOH solution
(4% w/v) was perfused for 30 min(1.6g EtOH/kg)
at a steady rate.
Experiment 2. Ratsweredivided into twoexperimental
groups (4 rats/experimental group), as follows : pretreat-
ment saline (control), or CY. The pretreatments of CY
were the same as in Experiment1, and PrOH solution
(4% w/v) was perfused for 30min (1.6g PrOH/kg) at
a steady rate.
EtOH, AcH, PrOH and propionaldehyde (PrCHO)
concentrations in each sample were quantitated by
the head-space GCmethod (12). The value of Kawas
calculated according to the previous report (9 -11, 13).
AcH was purchased fromMerck (Munchen, Germany).
All reagents except AcH were purchased fromWako
Pure Chemical (Osaka, Japan.).
Data were expressed as means±SD. Statistical anal-
ysis of the data was performed using the student’s t-test.
Values of p<0.05 were accepted as representing sig-
nificant differences. This study was approved by the
Kagawa Medical University Animal Investigation
Committee.
RESULTS
Figures 1 and 2 show the Ka values and peak AcH
concentrations, respectively from Experiment 1. The
value of the control group and CY group have been
published previously (11). TheKa value in the YOgroup
was significantly lower than that of the control, without
the high concentration of AcH.No additional decrease
in the value of Ka in the CY＋YO group was observed
in comparison with that of the YO-alone group, but
was significantly lower compared to the CY group.
The Ka values were not significantly different between
C6 and the control, CY＋C6 and CY, respectively.
Figure 1. Values of absorption rate constant (Ka).
CONTROL : control group, CY :cyanamide pretreated group, YO:
yohimbine hydrochloride pretreatedgroup,CY＋YO : cyanamidewith
yohimbine hydrochloride pretreated group, C6 : hexamethonium
bromide pretreated group, CY＋C6 : cyanamidewithhexamethonium
bromide pretreated group. The values are means±SD (n=5 or 7).
＊p<0.05 compared with control. ＊＊ p<0.05 compared with CY.
Figure 2. Peak blood acetaldehyde concentration for each treat-
ment group.
All abbreviations are same as in Figure 1.
The values are means±SD (n=5 or 7). ＊p<0.01 comparedwith control.
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Table 1 shows peak concentration of PrOH and
PrCHO for each group in Experiment 2. Mean blood
concentrations of PrCHO pretreated with CY groups
were increased markedly compared to the control
group and the value of Ka in the CY group was
significantly lower than in the control (Figure 3).
DISCUSSION
It is generally accepted that gastrointestinal function
is regulated by the autonomic nervous systems, divided
into three major parts including the sympathetic, the
parasympathetic and the enteric nervous system (ENS)
(14). Stimulation of the sympathetic nervous system
increases intestinal water and electrolyte absorption
(15, 16). The sympathetic nervous system exerts tonic
control on intestinal fluid transport and its effect ismainly
a direct action through peripheralα2-adrenergic recep-
tors on enterocytes (17). Therefore, YO, a selective
α2 -adrenergic blocking agent, decreases the basal
absorption rate of the jejunum. In the present study,
YO singularly demonstrated an anti-absorptive action
of ethanol. The value of Ka in CY with YO did not
significantly decrease compared to YO alone, but
additional inhibition of EtOH absorption was observed
in the CY＋YO group, compared to the CY group.
AcH activity may therefore be masked by the action
of YO, owing to its pharmacological effects and being
potent under our experimental conditions.
The α2 -adrenergic binding sites have been identified
in the dorsalmotornucleusof thevagusand in thenucleus
tractus solitarii, associated with gastrointestinal efferent
and afferent fibers, respectively (18). YO can easily enter
the central nervous system (19) andmayactdirectlywith
both peripheralα2 -adrenergic receptorson enterocytes
and centralα2 -adrenergic receptors leading to decreased
intestinal absorption (17). Inhibition of intestinal EtOH
absorption, due to YO,may bemediated throughvagus
nerve stimulation.
The PrCHO, an aliphatic aldehydes compoundsimilar
to AcH, suppresses intestinal absorption of PrOH. In
low concentration of PrCHO, it has sympathomimetic
properties similar toAcH(2, 20-22). It alsohas a pressor
effects and releases catecholamines from the adrenal
medulla and other tissues (20, 21, 23, 24). In high
dose (40mg/kg of PrCHO or AcH) administration,
the vagal stimulatory component may overpower the
sympathomimetic action and it is diminished by
atropine administration or abolished by vagotomy (25).
This also supports the concept that AcH action may
be due to vagal stimulation since the intestinal action
of AcH is abolished by atropine pretreatment (11).
It has been reported that ENS, the nerves of mu-
cosal surfaces, may play an important role with the
pathophysiology of the intestinal tract and that ENS
may contain adrenergic, cholinergic and non-adrenergic
non-cholinergic neurons (14). ENS participates in the
control of fluid and electrolyte movement over the
intestinal mucosa and hence may be influenced by
two common final pathways such as the cholinergic
and non-cholinergic pathways (14). In our previous
report, accumulation of AcH in blood stimulates
cholinergic neurons (11), but effects on the ganglionic
nicotinic receptor have not investigated yet. EtOH
absorption was not affected by pretreatment with
C6, an antagonist of the nicotinic ganglionic receptor,
as reported previously (26). The administration of C6
with CY also did not prevent the decrease in EtOH
absorption, suggesting that the nicotinic receptor does
not mediate AcH effects.
In conclusion, these observations indicate that a high
AcH concentration inbloodmaystimulate thevagusnerve
and both nicotinic-receptors andα2 -adrenoceptors have
little effect. Hence these data indirectly support the
Table 1. Peak blood concentration of 1-propanol andpropionaldehyde
in each group of Experiment 2 (n=4).
1-propanol (mM) propionaldehyde (µM)
Control
Cyanamide
22.5±3.2
17.6±3.0
3.9±1.0
303.9±40.6*
*p<0.001 compared with control. Values are means±SD.
Figure 3. Values of absorption rate constant (Ka) in each group
of Experiment 2.
The values are means±SD (n=4).
CY : cyanamide pretreated group, ＊p<0.01compared with control.
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hypothesis that cholinergic nerves mediate AcH action
in the gastrointestinal tract, via vagus nerve stimulation.
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